S100A9 and Sepsis: Here, using S100A9-KO mice and an S100A9 inhibitor in a CLP-induced sepsis model, we demonstrated for the first time that the ablation or inhibition of S100A9 significantly reduced CLP-induced mortality, liver dysfunction, cell apoptosis, inflammation, and oxidative stress in mice (Figure 2 and Figure 6), indicating that blocking S100A9 improves septic liver injury.